Results 121 to 130 of about 3,114 (145)

Nusinersen for spinal muscular atrophy.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Laboratory monitoring of nusinersen safety

Muscle & Nerve, 2021
AbstractIntroductionThis retrospective study reports our tertiary care center's experience with intrathecal nusinersen administration in children and adults with spinal muscular atrophy (SMA).MethodsWe reviewed safety monitoring laboratory results and need for procedural sedation and fluoroscopy‐guidance in all SMA patients receiving nusinersen between
Natalie L, Goedeker, Jennifer L, Gibbons, Arun S, Varadhachary, Anne M, Connolly, Craig M, Zaidman   +4 more
openaire   +2 more sources

Nusinersen

Reactions Weekly
  +10 more sources

Nusinersen

Reactions Weekly, 2021
  +6 more sources

Nusinersen (Spinraza)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Spinraza should not be reimbursed by public drug plans for the treatment of patients with type II and type III 5q spinal muscular atrophy (SMA) regardless of ambulatory status if initiated in patients older than 18 years of age. No randomized clinical trials evaluating the efficacy or safety of Spinraza in treatment ...
openaire   +1 more source

Nusinersen

Reactions Weekly, 2022
  +4 more sources

Nusinersen

Reactions Weekly, 2023
  +4 more sources

Nusinersen: First Global Approval

Drugs, 2017
Spinal muscular atrophy (SMA) is a rare autosomal recessive disorder characterized by muscle atrophy and weakness resulting from motor neuron degeneration in the spinal cord and brainstem. It is most commonly caused by insufficient levels of survival motor neuron (SMN) protein (which is critical for motor neuron maintenance) secondary to deletions or ...
openaire   +2 more sources

Nusinersen: A Treatment for Spinal Muscular Atrophy

Annals of Pharmacotherapy, 2018
Objective: To review the efficacy and safety of nusinersen (Spinraza) in the treatment of spinal muscular atrophy (SMA). Data Sources: An English-language literature search of PubMed and MEDLINE (1946 to June 2018) was performed using the terms nusinersen, ISIS-SMN (Rx), and spinal muscular atrophy.
Melanie K, Claborn, Debra L, Stevens, Cheri K, Walker, Brooke L, Gildon   +3 more
openaire   +2 more sources